Bleichroeder’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-971
Closed -$2.52K – 82
2024
Q1
$2.52K Hold
971
– – ﹤0.01% 79
2023
Q4
$3.5K Hold
971
– – ﹤0.01% 71
2023
Q3
$5.03K Hold
971
– – ﹤0.01% 67
2023
Q2
$8.28K Sell
971
-26,043
-96% -$267K ﹤0.01% 77
2023
Q1
$318K Hold
27,014
– – 0.07% 41
2022
Q4
$389K Hold
27,014
– – 0.08% 41
2022
Q3
$1.35M Hold
27,014
– – 0.28% 34
2022
Q2
$2.3M Hold
27,014
– – 0.48% 31
2022
Q1
$4.08M Hold
27,014
– – 0.72% 31
2021
Q4
$8.08M Hold
27,014
– – 1.26% 21
2021
Q3
$10.5M Hold
27,014
– – 1.71% 18
2021
Q2
$11.4M Hold
27,014
– – 1.72% 18
2021
Q1
$13.1M Buy
+27,014
New +$13.8M 2.21% 14

Other funds holding FNCH

Bleichroeder's FNCH Position: Q2 2024 in Review

Bleichroeder sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2024, closing a stake of 971 shares — an estimated $2.52K sold.

Bleichroeder first reported a position in FNCH in Q1 2021 and held it in 13 quarters. The position peaked at $13.1M in Q1 2021. 1 fund tracked by Wall St. Rank holds FNCH as of Q2 2024.

  • Bleichroeder reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Bleichroeder sold 971 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2024, an estimated $2.52K.
  • Bleichroeder first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
  • Bleichroeder's Finch Therapeutics Group, Inc. Common Stock position peaked at $13.1M in Q1 2021.
  • 1 fund tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2024.

Based on Bleichroeder's 13F filing for Q2 2024, filed 13 Aug 2024.